Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP)

Thrombosis and Haemostasis

Volumn 95, Issue 1, 2006, Pages 68-76

  Liu, Tongyao ^a   Scallan, Ciaran D ^a   Broze Jr , George J ^b   Patarroyo White, Susanna ^a   Pierce, Glenn F ^a   Johnson, Kirk W ^a  

^a Avigen Inc   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Coagulation; Fucoidan; Hemophilia; Sulfated polysaccharides; TFPI

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FUCOIDIN; HEPARIN; HEPARIN DERIVATIVE; PENTOSAN POLYSULFATE; POLYSACCHARIDE SULFATE; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; COAGULANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; LIPOPROTEINS; MICE; PENTOSAN SULFURIC POLYESTER; POLYSACCHARIDES; PROTHROMBIN TIME;

EID: 33645538085     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-0361     Document Type: Article

References (48)

1. Bishop P, Lawson J. Recombinant biologics for treatment of bleeding disorders. Nat Rev Drug Discov 2004; 3: 684-94.
2. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev 2004; 18: 101-13.
3. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004; 100: 722-30.
4. Lee JW. Von Willebrand disease, hemophilia A and B, and other factor deficiencies. Int Anesthesiol Clin 2004; 42: 59-76.
5. Bohn RL, Schramm W, Bullinger M et al. Outcome measures in haemophilia: more than just factor levels. Haemophilia 2004; 10 Suppl 1: 2-8.
6. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
7. Mann KG. Thrombin: can't live without it; probably die from it. Chest 2003; 124(Suppl): 1S-3S.
8. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
9. Broze GJ, Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
10. Broze GJ, Jr. The rediscovery and isolation of TFPI. J Thromb Haemost 2003; 1: 1671-5.
11. Johnson K, Hung D. Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway. Coron Artery Dis 1998; 9: 83-7.
12. Westrick RJ, Bodary PF, Xu Z et al. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001; 103: 3044-6.
13. Kleesiek K, Schmidt M, Gotting C et al. The 536C->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
14. Nordfang O, Valentin S, Beck TC et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-7.
15. Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res 1991; 64: 213-22.
16. Erhardtsen E, Ezban M, Madsen MT et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6: 388-94.
17. Toida TC, Chaidedgumjorn A, Linhardt RJ. Structure and bioactivity of sulfated polysaccharides. Trends in Glycoscience and Glycotechnology 2003; 15: 29-46.
18. Sinay P. Sugars slide into heparin activity. Nature 1999; 398: 377-8.
19. Bates SM, Weitz JI. The new heparins. Coron Artery Dis 1998; 9: 65-74.
20. Orgueira HA, Bartolozzi A, Schell P et al. Modular synthesis of heparin oligosaccharides. Chemistry 2003; 9: 140-69.
21. McAuliffe JC. Carbohydrate drugs - An ongoing challenge. Chemical Industry Magazine 1997; 3: 170-4.
22. Williams PD, Ye H, Cheng FC et al. Comparative effects of heparin and the sulfatoid GM 1474 on coagulation parameters in plasma and blood from various species. Gen Pharmacol 1998; 30: 337-41.
23. Wan JG, Mu JS, Zhu HS et al. N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002; 51: 435-43.
24. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289 (Pt 2): 313-30.
25. McCaffrey TA, Falcone DJ, Borth W et al. Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasia. Biochem Biophys Res Common 1992; 184: 773-81.
26. Luyt CE, Meddahi-Pelle A, Ho-Tin-Noe B et al. Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia. J Pharmacol Exp Ther 2003; 305: 24-30.
27. Novotny WF, Palmier M, Wun TC et al. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
28. Broze GJ, Jr., Lange GW, Duffin KL et al. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
29. Wesselsehmidt R, Likert K, Huang Z, MacPhail L, Broze GJ, Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-9.
30. Anderson L, Barrowcliffe TW, Helmer E et al. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res. 1976; 9: 575-83.
31. PDR Staff. Physicians' Desk Reference. Thomson PDR 2004.
32. National Research Council. Guide for the care and use of laboratory animals. Washington, D. C., National Academy Press; 1996.
33. Broze GJ, Jr., Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001; 85: 747-8.
34. MacGregor IR, Dawes J, Pepper DS et al. Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides-comparison with effects upon anticoagulant activity, lipolysis and platelet alpha-granule proteins. Thromb Haemost 1985; 53: 411-4.
35. Millet J, Jouault SC, Mauray S et al. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route. Thromb Haemost 1999; 81: 391-5.
36. Joffe S. Drug prevention of postoperative deep vein thrombosis. A compararative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 1976; 111: 37-40.
37. Lush RM, Figg WD, Pluda JM et al. A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Ann Oncol 1996; 7: 939-44.
38. Huang P, Auclair B, Beechinor D et al. Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis. Urology 1997; 50: 39-43.
39. Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology 2003; 13: 29R-40R.
40. Church FC, Meade JB, Treanor RE et al. Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin. J Biol Chem 1989; 264: 3618-23.
41. Giedrojc J, Klimiuk M, Radziwon P et al. Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model. J Cardiovasc Pharmacol 1999; 34: 340-5.
42. Granert C, Raud J, Waage A et al. Effects of polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit. Infect Immun 1999; 67: 2071-4.
43. Sweeney EA, Lortat-Jacob H, Priestley GV et al. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 2002; 99: 44-51.
44. Deux JF, Meddahi-Pelle A, Le Blanche AF et al. Low molecular weight fucoidan prevents neointimal hyperplasia in rabbit iliac artery in-stent restenosis model. Arterioscler Thromb Vasc Biol 2002; 22: 1604-9.
45. Dunn F, Soria J, Soria C et al. Fibrinogen binding on human platelets. Influence of different heparins and of pentosane polysulfate. Thromb Res 1983; 29: 141-8.
46. Klocking HP, Markwardt F. Release of plasminogen activator by pentosan polysulphate. Thromb Res 1986; 41: 739-44.
47. Durig J, Bruhn T, Zurborn KH et al. Anticoagulant fucoidan fractions from Fucus vesiculosus induce platelet activation in vitro. Thromb Res 1997; 85: 479-91.
48. Brummel Ziedins K, Rivard GE, Pouliot RL et al. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-44.